Clinical Trials Browser

Breast Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Prostatic Neoplasms, Castration-Resistant, Triple Negative Breast Neoplasms

NCT05932862 2025-09-05

A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Participants With Advanced Solid Tumors

Phase 1 Recruiting

429 enrolled

BreastGastrointestinalGenitourinaryGynecologic

Breast Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms

NCT06488378 2025-08-22

Phase Ib Study of Axatilimab in Combination With Olaparib in BRCA1/2 and PALB2- Associated Metastatic HER2-negative Breast Cancer

Phase 1 Recruiting

20 enrolled

Breast

Breast Neoplasms

NCT07090369 2025-07-29

LumOnate

Phase 1 Not yet recruiting

20 enrolled

Genitourinary

Prostatic Neoplasms

NCT07069335 2025-07-16

A Bioequivalence Study to Evaluate Pharmacokinetics and Safety of BR2022 and BR2022-1 in Patients With Deleterious or Suspected Deleterious Germline BRCA-Mutated Advanced Ovarian Cancer

Phase 1 Recruiting

24 enrolled

Gynecologic

Ovarian Neoplasms

NCT05870423 2025-06-05

PRRT-PARPi

Phase 1 Recruiting

24 enrolled

EndocrineNET

Neuroendocrine Tumors

NCT02419495 2025-06-04

Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies

Phase 1 Terminated

221 enrolled

BreastDermatologicGenitourinaryGynecologicThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Fallopian Tube Neoplasms, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Ovarian Neoplasms, Triple Negative Breast Neoplasms

NCT03874884 2025-05-14

LuPARP

Phase 1 Active not recruiting

70 enrolled

Genitourinary

Metastatic Castration Resistant Prostate Cancer (mCRPC)

NCT00516724 2025-04-11

Study to Assess the Safety and Tolerability of a PARP Inhibitor in Combination With Carboplatin and/or Paclitaxel

Phase 1 Completed

189 enrolled

BreastGynecologic

Triple Negative Metastatic Breast Cancer

NCT04236414 2025-04-04

Investigating Safety, Tolerability, Efficacy and PK of Olaparib in Paediatric Patients With Solid Tumours

Phase 1 Completed

16 enrolled

Tumor-Agnostic

Neoplasms

NCT03532880 2025-02-07

A Study of Olaparib and Low Dose Radiotherapy for Small Cell Lung Cancer

Phase 1 Completed

26 enrolled

Thoracic

Small Cell Lung Carcinoma

NCT06686745 2025-01-07

Study of SIM0508 Alone and in Combination in Patients With Advanced Solid Tumors

Phase 1 Recruiting

130 enrolled

Other solid neoplasm

Advanced Solid Tumors

NCT05358639 2024-11-18

Combination of Olaparib and Navitoclax in Women with HGSC and TNBC

Phase 1 Active not recruiting

36 enrolled

BreastGynecologic

Ovarian Neoplasms, Triple Negative Breast Neoplasms

NCT05258747 2024-10-03

A Crossover Bioequivalence Study of Olaparib Tablets, 150 mg (Lek Pharmaceuticals d.d.) and Lynparza® (Olaparib) Tablets 150 mg (AstraZeneca Pharmaceuticals LP), in Patients With Breast Cancer Gene (BRCA) Mutated Ovarian Cancer, Recurrent Ovarian Cancer or Metastatic Breast Cancer

Phase 1 Completed

70 enrolled 13 charts

BreastGynecologic

Breast Neoplasms, Ovarian Neoplasms

NCT02338622 2024-09-26

ComPAKT

Phase 1 Completed

60 enrolled

Advanced Cancer

NCT05807126 2024-05-02

Testing the Addition of Immunotherapy With Hu5F9-G4 (Magrolimab) to the Usual PARP Inhibitor, Olaparib for Treatment of Metastatic or Recurrent Breast or Castrate-Resistant Prostate Cancer With BRCA Mutations

Phase 1 Withdrawn

Genitourinary

Prostatic Neoplasms

NCT04586335 2024-03-21

Study of CYH33 in Combination With Olaparib an Oral PARP Inhibitor in Patients With Advanced Solid Tumors.

Phase 1 Terminated

24 enrolled

BreastGenitourinaryGynecologic

Breast Neoplasms, Hereditary Sensory and Autonomic Neuropathies, Ovarian Neoplasms, Prostatic Neoplasms, Endometrial Neoplasms

Clinical Trials

Olaparib and ASTX727 in BRCA1/2- and Homologous Recombination Deficient (HRD)-Mutated Tumors

ORCA-2

Testing the Addition of Abemaciclib to Olaparib for Women With Recurrent Ovarian Cancer

Testing the Combination of DS-8201a and Olaparib in HER2-Expressing Cancers With Expansion in Patients With Platinum Resistant Ovarian Cancer

Testing the Safety of the Anti-Cancer Drugs Durvalumab and Olaparib During Radiation Therapy for Locally Advanced Unresectable Pancreatic Cancer

Ascending Doses of Ceralasertib in Combination With Chemotherapy and/or Novel Anti Cancer Agents

Phase I Comparative Bioavailability Study

Bioequivalence Study of DWZ2501 in Patients With Advanced BRCA-mutated High-grade Ovarian Cancer

COD

Testing the Sequential Combination of the Anti-cancer Drugs Olaparib Followed by Adavosertib (AZD1775) in Patients With Advanced Solid Tumors With Selected Mutations and PARP Resistance, STAR Study

Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors

Selumetinib and Olaparib in Solid Tumors

LuPARP

Study of INCB123667 in Subjects With Advanced Solid Tumors

Phase Ib Trial of the KRAS G12C Inhibitor Adagrasib (MRTX849) in Combination With the PARP Inhibitor Olaparib in Patients With KRAS G12C Mutated Advanced Solid Tumors, With a Focus on Gynecological, Breast, Pancreatic and KEAP1 Mutated Non-small Cell Lung Cancers

Radiotherapy and Durvalumab/Durvalumab Combo (Tremelimumab/Olaparid) for Small Cell Lung Cancer

Olaparib in Combination With Vorinostat in Patients With Relapsed/Refractory and/or Metastatic Breast Cancer

RADIOSARP

Phase 1b Trial of BMS-986504 in Combination With Olaparib in Patients With MTAP Loss

Olaparib + Sapacitabine in BRCA Mutant Breast Cancer

Study of SIM0501 Alone and in Combination in Patients With Advanced Solid Tumors

POLAR

HOPE: Olaparib, Palbociclib and Fulvestrant in Patients With BRCA Mutation-associated, HR+, HER2-metastatic Breast Cancer

Cirtuvivint/Olaparib in Breast Cancer Susceptibility Gene/Homologous Recombination Deficiency Platinum Resistant Ovarian Cancer

mTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial and Ovarian

BISCAY

Hyperthermia and Olaparib in Treating Breast Cancer Patients With Chest Wall Recurrences

Phase I Study of Olaparib and Temozolomide for Ewings Sarcoma or Rhabdoomyosarcoma

CONCORDE

A Phase 1 Study of RO7623066 Alone and in Combination in Patients With Advanced Solid Tumors

RadioPARP

PHOEBE

Olaparib and High-Dose Chemotherapy in Treating Patients With Relapsed or Refractory Lymphomas Undergoing Stem Cell Transplant

NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors

A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Participants With Advanced Solid Tumors

Phase Ib Study of Axatilimab in Combination With Olaparib in BRCA1/2 and PALB2- Associated Metastatic HER2-negative Breast Cancer

LumOnate

A Bioequivalence Study to Evaluate Pharmacokinetics and Safety of BR2022 and BR2022-1 in Patients With Deleterious or Suspected Deleterious Germline BRCA-Mutated Advanced Ovarian Cancer

PRRT-PARPi

Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies

LuPARP

Study to Assess the Safety and Tolerability of a PARP Inhibitor in Combination With Carboplatin and/or Paclitaxel

Investigating Safety, Tolerability, Efficacy and PK of Olaparib in Paediatric Patients With Solid Tumours

A Study of Olaparib and Low Dose Radiotherapy for Small Cell Lung Cancer

Study of SIM0508 Alone and in Combination in Patients With Advanced Solid Tumors

Combination of Olaparib and Navitoclax in Women with HGSC and TNBC

A Crossover Bioequivalence Study of Olaparib Tablets, 150 mg (Lek Pharmaceuticals d.d.) and Lynparza® (Olaparib) Tablets 150 mg (AstraZeneca Pharmaceuticals LP), in Patients With Breast Cancer Gene (BRCA) Mutated Ovarian Cancer, Recurrent Ovarian Cancer or Metastatic Breast Cancer

ComPAKT

Testing the Addition of Immunotherapy With Hu5F9-G4 (Magrolimab) to the Usual PARP Inhibitor, Olaparib for Treatment of Metastatic or Recurrent Breast or Castrate-Resistant Prostate Cancer With BRCA Mutations

Study of CYH33 in Combination With Olaparib an Oral PARP Inhibitor in Patients With Advanced Solid Tumors.